HOOKIPA Pharma (HOOK)
(Delayed Data from NSDQ)
$0.77 USD
0.00 (-0.22%)
Updated May 13, 2024 04:00 PM ET
After-Market: $0.76 -0.01 (-0.82%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for HOOKIPA Pharma Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 20 | 14 | 18 | 20 | 12 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 20 | 14 | 18 | 20 | 12 |
Selling & Adminstrative & Depr. & Amort Expenses | 118 | 87 | 100 | 73 | 63 |
Income After Depreciation & Amortization | -98 | -73 | -82 | -53 | -51 |
Non-Operating Income | 17 | 9 | 7 | 10 | 9 |
Interest Expense | 0 | 1 | 1 | 1 | 1 |
Pretax Income | -81 | -65 | -76 | -44 | -43 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -82 | -65 | -76 | -44 | -43 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -82 | -65 | -76 | -44 | -43 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -94 | -70 | -77 | -49 | -50 |
Depreciation & Amortization (Cash Flow) | 4 | 4 | 5 | 4 | 1 |
Income After Depreciation & Amortization | -98 | -73 | -82 | -53 | -51 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 94.86 | 65.57 | 32.90 | 26.08 | 17.86 |
Diluted EPS Before Non-Recurring Items | -0.75 | -0.99 | -2.30 | -1.69 | -2.41 |
Diluted Net EPS (GAAP) | -0.86 | -0.99 | -2.30 | -1.69 | -2.41 |
Fiscal Year end for HOOKIPA Pharma Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 36.60 | 7.41 | 6.87 | 2.68 | 3.18 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 36.60 | 7.41 | 6.87 | 2.68 | 3.18 |
SG&A, R&D, and Dept/Amort Expenses | 25.50 | 25.53 | 29.54 | 24.16 | 25.83 |
Income After SG&A, R&D, and Dept/Amort Expenses | 11.10 | -18.12 | -22.67 | -21.48 | -22.65 |
Non-Operating Income | 3.28 | 6.29 | 3.65 | 3.55 | 3.30 |
Interest Expense | 0.00 | 0.05 | 0.05 | 0.10 | 0.12 |
Pretax Income | 14.38 | -24.66 | -19.07 | -18.02 | -19.48 |
Income Taxes | 0.00 | 0.16 | 0.00 | 0.00 | 0.21 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 14.38 | -24.82 | -19.07 | -18.02 | -19.68 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 14.38 | -24.82 | -19.07 | -18.02 | -19.68 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 130.76 | 112.81 | 112.15 | 81.89 | 72.89 |
Diluted EPS Before Non-Recurring Items | 0.12 | -0.11 | -0.17 | -0.22 | -0.27 |
Diluted Net EPS (GAAP) | 0.11 | -0.20 | -0.17 | -0.22 | -0.27 |